73

Oncology
Prevention and treatment of tumors, and caring for cancer patients.
Sub Categories on Oncology
{{items.name}}
α-KG-dependent glycolysis activation by BCAT1 contributes to EGFR-TKI resistance in NSCLC
Oncology
α-KG-dependent glycolysis activation by BCAT1 contributes to EGFR-TKI resistance in NSCLC
November 28,2024
Latest Articles
Researchers discover resistance to liver cancer treatment

Researchers discover resistance to liver cancer treatment

byUniversity of Hawaii at ManoaCredit: Pixabay/CC0 Public DomainLiver cancer is the fourth deadliest cancer in Hawaiʻi, particularly affecting Native Hawaiian, Filipino and Japanese men. Patient
Updated on: October 31,2023
Researchers discover resistance to liver cancer treatment

Researchers discover resistance to liver cancer treatment

byUniversity of Hawaii at ManoaCredit: Pixabay/CC0 Public DomainLiver cancer is the fourth deadliest cancer in Hawaiʻi, particularly affecting Native Hawaiian, Filipino and Japanese men. Patient
Updated on:October 31,2023
ctDNA Could Serve as a Prognostic Tool in China for Predicting Outcomes in DLBCL

ctDNA Could Serve as a Prognostic Tool in China for Predicting Outcomes in DLBCL

September 12, 2022Lisa AstorResults from a retrospective analysis presented during the 2022 ESMO Congress indicated that circulating tumor DNA could potentially be leveraged as a prognostic factor and
Updated on: October 24,2023
ctDNA Could Serve as a Prognostic Tool in China for Predicting Outcomes in DLBCL

ctDNA Could Serve as a Prognostic Tool in China for Predicting Outcomes in DLBCL

September 12, 2022Lisa AstorResults from a retrospective analysis presented during the 2022 ESMO Congress indicated that circulating tumor DNA could potentially be leveraged as a prognostic factor and
Updated on:October 24,2023
New near-infrared activated photo-oxidants kill cancer cells without oxygen

New near-infrared activated photo-oxidants kill cancer cells without oxygen

A research team led by scientists from City University of Hong Kong (CityU) has achieved a significant breakthrough by inventing a new class of near-infrared-activated photo-oxidants that can effectiv
Updated on: November 12,2023
New near-infrared activated photo-oxidants kill cancer cells without oxygen

New near-infrared activated photo-oxidants kill cancer cells without oxygen

A research team led by scientists from City University of Hong Kong (CityU) has achieved a significant breakthrough by inventing a new class of near-infrared-activated photo-oxidants that can effectiv
Updated on:November 12,2023
Report: Cancer deaths continue downward trend, modest improvements in survival for pancreatic cancer

Report: Cancer deaths continue downward trend, modest improvements in survival for pancreatic cancer

byNational Cancer InstituteAge-standardized, delay-adjusted overall cancer incidence rates (2014–2018) and age-standardized overall cancer death rates (2015–2019) are illustrated for all cancer
Updated on: December 19,2023
Report: Cancer deaths continue downward trend, modest improvements in survival for pancreatic cancer

Report: Cancer deaths continue downward trend, modest improvements in survival for pancreatic cancer

byNational Cancer InstituteAge-standardized, delay-adjusted overall cancer incidence rates (2014–2018) and age-standardized overall cancer death rates (2015–2019) are illustrated for all cancer
Updated on:December 19,2023
New research discovers gene mutations linked to prostate cancer

New research discovers gene mutations linked to prostate cancer

A study led by scientists from the Center for Genetic Epidemiology at the Keck School of Medicine of USC and USC Norris Comprehensive Cancer Center has made a significant leap in our understanding of
Updated on: October 31,2023
New research discovers gene mutations linked to prostate cancer

New research discovers gene mutations linked to prostate cancer

A study led by scientists from the Center for Genetic Epidemiology at the Keck School of Medicine of USC and USC Norris Comprehensive Cancer Center has made a significant leap in our understanding of
Updated on:October 31,2023
EMA Accepts Marketing Application for Odronextamab in R/R DLBCL or Follicular Lymphoma

EMA Accepts Marketing Application for Odronextamab in R/R DLBCL or Follicular Lymphoma

August 17, 2023Chris RyanThe European Medicines Agency has accepted a marketing authorization application seeking the approval of odronextamab for the treatment of adult patients with relapsed/refract
Updated on: October 12,2023
EMA Accepts Marketing Application for Odronextamab in R/R DLBCL or Follicular Lymphoma

EMA Accepts Marketing Application for Odronextamab in R/R DLBCL or Follicular Lymphoma

August 17, 2023Chris RyanThe European Medicines Agency has accepted a marketing authorization application seeking the approval of odronextamab for the treatment of adult patients with relapsed/refract
Updated on:October 12,2023
Targeted therapy momelotinib provides significant symptom and anemia improvements in patients with myelofibrosis

Targeted therapy momelotinib provides significant symptom and anemia improvements in patients with myelofibrosis

byUniversity of Texas M. D. Anderson Cancer CenterCredit: Unsplash/CC0 Public DomainPatients with myelofibrosis had clinically significant improvement in disease-related symptoms, including anem
Updated on: December 19,2023
Targeted therapy momelotinib provides significant symptom and anemia improvements in patients with myelofibrosis

Targeted therapy momelotinib provides significant symptom and anemia improvements in patients with myelofibrosis

byUniversity of Texas M. D. Anderson Cancer CenterCredit: Unsplash/CC0 Public DomainPatients with myelofibrosis had clinically significant improvement in disease-related symptoms, including anem
Updated on:December 19,2023
FDA approval of 4-drug combination for front-line treatment of metastatic pancreatic cancer

FDA approval of 4-drug combination for front-line treatment of metastatic pancreatic cancer

by Denise Heady,University of California, Los AngelesKaplan–Meier estimates of overall survival (A) and progression-free survival (B) NALIRIFOX=liposomal irinotecan in combination with fluoroura
Updated on: March 22,2024
FDA approval of 4-drug combination for front-line treatment of metastatic pancreatic cancer

FDA approval of 4-drug combination for front-line treatment of metastatic pancreatic cancer

by Denise Heady,University of California, Los AngelesKaplan–Meier estimates of overall survival (A) and progression-free survival (B) NALIRIFOX=liposomal irinotecan in combination with fluoroura
Updated on:March 22,2024
The phenotypic plasticity effect of cancer cells and how to exploit it

The phenotypic plasticity effect of cancer cells and how to exploit it

by Michael Hesse,Max Planck SocietyMathematical model of tumor heterogeneity and phenotype switching: A detailed analysis. Credit: M.Raatz, MPI for Evolutionary BiologyCancer cells are notorious
Updated on: October 31,2023
The phenotypic plasticity effect of cancer cells and how to exploit it

The phenotypic plasticity effect of cancer cells and how to exploit it

by Michael Hesse,Max Planck SocietyMathematical model of tumor heterogeneity and phenotype switching: A detailed analysis. Credit: M.Raatz, MPI for Evolutionary BiologyCancer cells are notorious
Updated on:October 31,2023
More News
Categories
Allergy&Clinical immunology
Anesthesiology & Pain
Cardiovascular Diseases
Dermatology
Diabetes & Endocrinology
Emergency Medicine & Critical Care
ENT & HN
Family Medicine
Gastroenterology
General Surgery
Geriatrics
Hematology&Oncology
Infectious Diseases
Nephrology & Urology
Neurology
Nutrition
OB & GYN
Ophthalmology
Orthopedics & Sports medicine
Pediatrics
Plastic Surgery
Psychiatry & Mental Health
Public Health & Prevention
Pulmonology
Rheumatology
Stomatology
Sleep
FIND US ON
ABOUT
Who We Are
Contact Us
Editorial Team
Sitemap
Policy
Privacy Policy
Advertising Policy
Editorial Policy
Corrections Policy
Medical Disclaimer
Alliance
wmo.com
sleep.net
pharm.net
doctors.net
worldsleep.com